MINT I – Multi-Institutional Neoadjuvant Therapy, MammaPrint Project I

Publication Name: Cancer Research

Author(s): Charles Cox, Peter Blumencranz, Douglas Reintgen, Ruben Saez, Nicole Howard, Jessica Gibson, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück

Treatment of locally advanced breast cancer (LABC) with neoadjuvant chemotherapy measures the in vivo response to chemotherapy,1 assesses long-term clinical outcomes associated with that response2,3 and enables some patients to undergo breast-conservation therapy due to therapeutic down-staging of the tumor.  In the current study, the chemosensitivity predictiveness of MammaPrint and BluePrint will be assessed in patients receiving neoadjuvant chemotherapy in the clinical diagnostic setting.

See Poster